Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Current Deferred Revenue: 2013-2015

Historic Current Deferred Revenue for Amphastar Pharmaceuticals (AMPH) over the last 3 years, with Dec 2015 value amounting to $643,000.

  • Amphastar Pharmaceuticals' Current Deferred Revenue rose 29.08% to $830,000 in Q3 2016 from the same period last year, while for Sep 2016 it was $830,000, marking a year-over-year increase of 29.08%. This contributed to the annual value of $643,000 for FY2015, which is 95.41% down from last year.
  • As of FY2015, Amphastar Pharmaceuticals' Current Deferred Revenue stood at $643,000, which was down 95.41% from $14.0 million recorded in FY2014.
  • Amphastar Pharmaceuticals' Current Deferred Revenue's 5-year high stood at $14.0 million during FY2014, with a 5-year trough of $643,000 in FY2013.
  • For the 3-year period, Amphastar Pharmaceuticals' Current Deferred Revenue averaged around $5.1 million, with its median value being $643,000 (2015).
  • Its Current Deferred Revenue has fluctuated over the past 5 years, first skyrocketed by 2,079.32% in 2014, then slumped by 95.41% in 2015.
  • Yearly analysis of 3 years shows Amphastar Pharmaceuticals' Current Deferred Revenue stood at $643,000 in 2013, then surged by 2,079.32% to $14.0 million in 2014, then slumped by 95.41% to $643,000 in 2015.